<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489696</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-080</org_study_id>
    <secondary_id>2010-018690-38</secondary_id>
    <nct_id>NCT01489696</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin</brief_title>
  <official_title>A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to compare blood pressure and pulse in male healthy subjects taking mirabegron
      and tamsulosin both alone and in combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment arm 1 (effect of mirabegron on tamsulosin): Subjects are randomized into one of two
      sequences.

      Subjects receive 2 singles doses of tamsulosin, once in the absence of mirabegron and once in
      the presence of mirabegron.

      24-hour Cardiovascular (CV) profiles are taken at both baseline days and after the single
      dose of tamsulosin /combination dose in each sequence. Regular blood samples are also taken
      to check for a potential Pharmacokinetic (PK) interaction.

      Treatment arm 2 (effect of tamsulosin on mirabegron): Subjects are randomized into one of two
      sequences.

      Subjects receive 2 singles doses of mirabegron, once in the absence of tamsulosin and once in
      the presence of tamsulosin.

      24-hour CV profiles are taken at both baseline days and after the single dose of
      mirabegron/combination dose in each sequence. Regular blood samples are also taken to check
      for a potential PK interaction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular interactions assessed by blood pressure and pulse rate</measure>
    <time_frame>Pre-dose until 24 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monitoring of safety and tolerability through assessment of vital signs, ECG, clinical safety laboratory and adverse events</measure>
    <time_frame>Arm 1: From time of combination dose until 4 days after combination dose / Arm 2: From time of combination dose until 8 days after combination dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential PK interaction of the combination dosing assessed by serial plasma sampling</measure>
    <time_frame>Arm 1: From time of combination dose until 4 days after combination dose (10 time points) / Arm 2: From time of combination dose until 8 days after combination dose (14 time points)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Cardiovascular</condition>
  <condition>Healthy Subjects</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tamsulosin singles doses; mirabegron multiple dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mirabegron single doses; tamsulosin multiple dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirabegron</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <other_name>YM178</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamsulosin</intervention_name>
    <description>oral</description>
    <arm_group_label>Treatment Arm 1</arm_group_label>
    <arm_group_label>Treatment Arm 2</arm_group_label>
    <other_name>Flomax</other_name>
    <other_name>Harnal</other_name>
    <other_name>Omnic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index more than or equal to 18.5 and less than 30.0 kg/m2

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to mirabegron and/or tamsulosin HCl, or any
             components of the formulations used

          -  Any of the liver function tests (i.e. Alanine Aminotransferase (ALT) and Asparate
             Aminotransferase (AST) above the upper limit of normal at repeated measures (at least
             one more time)

          -  Any clinically significant history of asthma, eczema, any other allergic condition or
             previous severe hypersensitivity to any drug (excluding non-active hay fever)

          -  Any prior clinically significant psychiatric history including hospitalization for
             mental health management

          -  Subject is at risk of urinary retention based on medical history

          -  Any clinically significant abnormality following the investigator's review of the
             pre-study physical examination, Electrocardiogram (ECG) and clinical laboratory tests

          -  Heart rate and/or blood pressure measurements at the screening and admission visits as
             follows: Heart rate &lt;50 or &gt;90 bpm; mean systolic blood pressure &lt;90 mm Hg or &gt;140
             mmHg (&gt;160 mmHg for subjects 65 years or older); mean diastolic blood pressure &lt;60 mm
             Hg or &gt;90 mmHg (&gt;100 mmHg for subjects 65 years or older) (blood pressure measurements
             to be taken after subject has been resting in supine position for 5 min; heart rate
             will be measured automatically; both to be taken in triplicate)

          -  A QTc interval of &gt; 430 ms after repeated measurements (at least two more times), a
             history of syncope, orthostatic hypotension, vertigo, cardiac arrest, unexplained
             cardiac arrhythmias or torsades de pointes, structural heart disease, or a family
             history of Long QT Syndrome (LQTS)

          -  A hemoglobin value &lt;12.5 g/dl (7.8 mmol/l) and/or a hematocrit value &lt;37.9% and/or a
             Red Blood Cell count &lt;4.08 T/l (4080 mm3)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance CRU Ltd</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=770</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2011</study_first_submitted>
  <study_first_submitted_qc>December 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2011</study_first_posted>
  <last_update_submitted>December 6, 2013</last_update_submitted>
  <last_update_submitted_qc>December 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>Tamsulosin</keyword>
  <keyword>Phase 1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

